Skip to main content
. 2011 Aug 11;61(1):41–48. doi: 10.1007/s00262-011-1089-0

Fig. 4.

Fig. 4

Survival outcomes of individual patients participating in the expanded access program. Among 13 treated patients, three had best overall response (BOR) of stable disease (SD) and 10 had progressive disease (PD). Median overall survival for all patients was 36 weeks (range 2–172+ weeks; including one patient with ongoing SD at the time of manuscript preparation)